Clinical Trial: A Multicenter, Open-label, Prospective Phase III Clinical Trial to Evaluate INR101 Injection for PET/CT Imaging in Patients With Prostate Cancer.

Posted On: 2025-04-12

U.S., April 12 -- ClinicalTrials.gov registry received information related to the study (NCT06922903) titled 'A Multicenter, Open-label, Prospective Phase III Clinical Trial to Evaluate INR101 Injection for PET/CT Imaging in Patients With Prostate Cancer.' on April 03.

Brief Summary: A multicenter, open-label, prospective Phase III clinical trial to evaluate INR101 injection for PET/CT imaging in patients with Prostate Cancer

Study Start Date: April, 2025

Study Type: INTERVENTIONAL

Condition: Prostate Cancer

Intervention: DRUG: INR101

INR101

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Yunhe Pharmaceutical (Tianjin) Co., Ltd

Published by HT Digital Content Services with permission from Health Daily Digest....

Click here to read full article from source

To read the full article or to get the complete feed from this publication, please Contact Us.

Exclusive

Category

Source

Publication

Location

Clinical Trial: A Multicenter, Open-label, Prospective Phase III Clinical Trial to Evaluate INR101 Injection for PET/CT Imaging in Patients With Prostate Cancer.